Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
July 2020
-
Media ReleaseNovartis receives Piqray® approval in Europe – the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutationPiqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial…
-
Media ReleaseSandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in EuropeSandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe Planned combined investment of more than EUR 150…
-
Media ReleaseNew Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus afliberceptA post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept…
-
Media ReleaseNovartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell diseaseIf approved, Adakveo would be the first targeted sickle cell disease therapy available for use in Europe CHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-…
-
Media ReleaseNovartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpointsJakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1…
-
Key ReleaseNovartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):…
-
Media ReleaseNovartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19…
-
Media ReleaseNovartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthmaOnce-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care…
-
Media ReleaseNovartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EUEuropean Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with…
-
Key ReleaseNovartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologiesCompany finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related…
-
Media ReleaseSandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® caseSandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic…
Pagination
- ‹ Previous page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- …
- 88
- › Next page